ThisiscontentfromElsevier'sDrugInformation
Maralixibat
Learn more about Elsevier's Drug Information today! Get the drug data and decision support you need, including TRUE Daily Updates™ including every day including weekends and holidays.
NOTE: Use only the 9.5 mg/mL oral solution for Alagille syndrome (ALGS).[67014]
NOTE: Maralixibat is designated as an orphan drug by the FDA for this indication.
190 mcg/kg/dose PO once daily 30 minutes before a meal in the morning; increase to 380 mcg/kg/dose PO once daily after 1 week, as tolerated (Max: 28.5 mg/day (3 mL) for the oral solution and 30 mg/day for the oral tablet).[67014]
190 mcg/kg/dose PO once daily 30 minutes before a meal in the morning; increase to 380 mcg/kg/dose PO once daily after 1 week, as tolerated (Max: 28.5 mg/day (3 mL) for the oral solution and 30 mg/day for the oral tablet).[67014]
NOTE: Use only the 19 mg/mL oral solution for progressive familial intrahepatic cholestasis (PFIC).[67014]
NOTE: Not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein.[67014]
NOTE: Maralixibat is designated as an orphan drug by the FDA for this indication.
285 mcg/kg/dose PO once daily 30 minutes before a meal in the morning; increase to 285 mcg/kg/dose PO twice daily, 428 mcg/kg/dose PO twice daily, and then to 570 mcg/kg/dose PO twice daily, as tolerated (Max: 38 mg/day (2 mL) for oral solution, 40 mg/day for oral tablets).[67014]
285 mcg/kg/dose PO once daily 30 minutes before a meal in the morning; increase to 285 mcg/kg/dose PO twice daily, 428 mcg/kg/dose PO twice daily, and then to 570 mcg/kg/dose PO twice daily, as tolerated (Max: 38 mg/day (2 mL) for oral solution, 40 mg/day for oral tablets).[67014]
380 mcg/kg/day (Max: 28.5 mg/day for oral solution, 30 mg/day for tablets) PO for Alagille syndrome; 1,140 mcg/kg/day (Max: 38 mg/day for oral solution, 40 mg/day for tablets) PO for progressive familial intrahepatic cholestasis.
380 mcg/kg/day (Max: 28.5 mg/day for oral solution, 30 mg/day for tablets) PO for Alagille syndrome; 1,140 mcg/kg/day (Max: 38 mg/day for oral solution, 40 mg/day for tablets) PO for progressive familial intrahepatic cholestasis.
380 mcg/kg/day (Max: 28.5 mg/day for oral solution, 30 mg/day for tablets) PO for Alagille syndrome; 1,140 mcg/kg/day (Max: 38 mg/day for oral solution, 40 mg/day for tablets) PO for progressive familial intrahepatic cholestasis.
380 mcg/kg/day (Max: 28.5 mg/day for oral solution, 30 mg/day for tablets) PO for Alagille syndrome; 1,140 mcg/kg/day (Max: 38 mg/day for oral solution, 40 mg/day for tablets) PO for progressive familial intrahepatic cholestasis.
3 to 11 months: 380 mcg/kg/day (Max: 28.5 mg/day for oral solution, 30 mg/day for tablets) PO for Alagille syndrome. Safety and efficacy have not been established for progressive familial intrahepatic cholestasis.
1 to 2 months: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Reduce the dosage or interrupt treatment if new onset hepatic function abnormalities occur. Once hepatic function returns to baseline or stabilizes at a new baseline, consider restarting maralixibat at the last tolerated dose, and increase the dose as tolerated. Consider permanent discontinuation if abnormalities in liver tests recur or symptoms consistent with clinical hepatitis are observed. Permanently discontinue treatment if a patient experiences a hepatic decompensation event (e.g., variceal hemorrhage, ascites, hepatic encephalopathy).[67014]
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
† Off-label indicationMaralixibat is an ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in individuals with Alagille syndrome (ALGS) or progressive familial intrahepatic cholestasis (PFIC).[67014] ALGS is a rare, genetic disorder that can affect multiple organ systems, including the liver, heart, skeleton, eyes, and kidneys. ALGS causes abnormalities in the bile ducts that can progress to liver disease. Individuals may present in the first 3 months of life with cholestasis, jaundice, poor weight gain and growth, and pruritus. The most prominent and problematic manifestation of ALGS is pruritus, which can lead to physical abrasions and scarring, as well as functional impacts (e.g., sleep and mood disorders) and deterioration in quality of life. Prior to maralixibat, treatment relied on supportive pharmacologic therapy for symptomatic relief (e.g., ursodeoxycholic acid, cholestyramine, antihistamines) or surgical intervention (e.g., liver transplantation).[67023][66823] PFIC is an infantile hereditary disorder in bile formation that can result in chronic liver disease. Symptoms may begin to appear soon after birth. Pruritus is the most significant clinical manifestation and can affect school, sleep, and overall quality of life.[70460] Individuals with ALGS (n = 31) and individuals with PFIC (n = 64) treated with maralixibat during clinical trials demonstrated greater improvement in pruritus compared to placebo, based on caregiver-reported outcome. The most common adverse reactions are diarrhea, liver function test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency. Monitor hepatic function and fat-soluble vitamin concentrations at baseline and periodically throughout treatment. Maralixibat was FDA-approved in 2021.[67014]
For storage information, see the specific product information within the How Supplied section.
NOTE: There are 2 different strengths of maralixibat oral solution available (9.5 mg/mL and 19 mg/mL), which should not be substituted for one another. Special attention should be given to the accurate calculation of the dose volume, particularly in pediatric patients younger than 5 years as the oral solution contains 364.5 mg/mL of propylene glycol. Use the 9.5 mg/mL formulation for treatment of ALGS. Use the 19 mg/mL formulation in patients with PFIC in order to minimize exposure to excipients, including propylene glycol.[67014]
Treatment-emergent elevated hepatic enzymes were observed during maralixibat clinical trials. Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were reported in 17% to 19% of maralixibat-treated individuals. In a pooled analysis of individuals with Alagille syndrome receiving maralixibat treatment (n = 86), ALT increases to more than 3 times baseline occurred in 26% of individuals and increases to more than 5 times baseline occurred in 3% of individuals. AST increases to more than 3 times baseline occurred in 16% of maralixibat-treated individuals and an increase to more than 5 times baseline occurred in 1 individual. Increased ALT led to treatment discontinuation in 7 (8%) individuals and dose reduction or treatment interruption in 3 (4%) individuals. In most individuals, the elevations resolved or improved after treatment discontinuation or dose modification. In some individuals, the elevations resolved or improved without dosing modification. Elevations in transaminases were asymptomatic and not associated with bilirubin elevations or other laboratory abnormalities. Increases in bilirubin above baseline were reported in 4 individuals (5%); maralixibat was discontinued in 2 of these individuals who had elevated bilirubin at baseline. In a clinical trial involving individuals with progressive familial intrahepatic cholestasis, 2 individuals experienced drug-induced liver injury (DILI) attributable to maralixibat. One individual received 570 mg/kg twice daily and the second individual required dose interruption and reduction. Two additional individuals experienced DILI in the open-label extension of the trial. Of these 4 individuals, 1 individual required a liver transplant and another individual died. Two maralixibat-treated individuals developed cholangitis or cholecystitis within 3 weeks of drug discontinuation (84 days and 130 days after maralixibat treatment initiation). Four maralixibat-treated individuals developed cholecystitis or cholangitis in the open-label extension portion of Trial 2; the average time to onset was 281 days. Increased gamma-glutamyltransferase was reported during postmarketing experience. Monitor hepatic enzymes, bilirubin, and INR at baseline and frequently during treatment. Decrease dose or interrupt treatment if new onset hepatic function abnormalities occur. Once hepatic function returns to baseline or stabilizes at a new baseline, consider restarting maralixibat at the last tolerated dose and increase as tolerated. Consider treatment discontinuation for persistent or recurrent hepatic function abnormalities or development of symptoms consistent with clinical hepatitis. Permanently discontinue treatment if an individual progresses to portal hypertension or experiences a hepatic decompensation (i.e., variceal hemorrhage, ascites, hepatic encephalopathy) event.[67014]
Diarrhea, abdominal pain, and vomiting are the most commonly reported adverse reactions in maralixibat-treated individuals. Diarrhea was reported in 56% to 57% of maralixibat-treated individuals during clinicals trials. Abdominal pain, defined as abdominal discomfort, abdominal distension, abdominal pain, lower abdominal pain, and upper abdominal pain, occurred in 28% to 54% of maralixibat-treated individuals during clinicals trials. Vomiting (41%), nausea (8%), and hematochezia (rectal GI bleeding; 9%) were also reported. Treatment interruptions or dose reductions occurred in 5 (6%) individuals with Alagille syndrome due to diarrhea, abdominal pain, or vomiting. In individuals with progressive familial intrahepatic cholestasis, diarrhea was the most frequent adverse reaction. Most episodes were mild and transient with a median duration of 5.5 days; however, 40% of individuals had diarrhea for at least 7 days. Treatment interruptions or dose reductions occurred in 3 (6%) individuals due to diarrhea or vomiting. A decrease in hemoglobin of at least 2 g/dL from baseline occurred in 17% of maralixibat-treated individuals. During postmarketing experience, hematemesis, liver transplant, post-endoscopy bleeding, and post-liver biopsy bleeding have been reported. Consider reducing the dosage or interrupt treatment if individuals experience persistent diarrhea or abdominal pain or have diarrhea with accompanying signs and symptoms such as bloody stool, vomiting, dehydration requiring treatment, or fever. Consider discontinuing treatment if symptoms persist and no alternate etiology is identified. Monitor for dehydration due to diarrhea and treat promptly. Once diarrhea and/or vomiting have resolved, restart maralixibat at the last tolerated dose and increase the dose as tolerated. Consider discontinuing treatment if symptoms occur upon rechallenge.[67014]
Maralixibat may affect the absorption of fat-soluble vitamins (A, D, E, and K) resulting in vitamin A deficiency, vitamin D deficiency, vitamin E deficiency, vitamin K deficiency, and bleeding. In clinical trials, fat-soluble vitamin (FSV) deficiency, defined as A, D, E, or K deficiency, or INR increase, was reported in 10% to 28% of maralixibat-treated individuals. Intracranial bleeding has been reported during postmarketing experience. If bleeding occurs, interrupt treatment with maralixibat. Maralixibat can be restarted once FSV deficiency is corrected and bleeding has resolved. Obtain serum fat-soluble vitamin concentrations and INR (to monitor for vitamin K) at baseline and periodically during treatment. Supplement with fat-soluble vitamins if a deficiency is diagnosed. Discontinue maralixibat if the deficiency persists or worsens despite supplementation.[67014]
Bone fractures, defined as tibia fracture, femur fracture, foot fracture, humerus fracture, radius fracture, ulna fracture, hand fracture, clavicle fracture, rib fracture, and pathological fracture, were reported in 6% to 9% of maralixibat-treated individuals. In a clinical trial involving individuals with progressive familial intrahepatic cholestasis, 3 individuals developed bone fractures with a median time to bone fracture of 73 days. In the open-label portion of the trial, 2 individuals developed bone fractures with an average time to onset of 204 days. If a fracture occurs, consider interrupting maralixibat therapy and supplement with fat soluble vitamins (FSV). Therapy can be restarted once FSV deficiency is corrected and maintained at corrected concentrations.[67014]
Maralixibat is contraindicated in individuals with prior or active decompensated hepatic cirrhosis (e.g., variceal hemorrhage, ascites, hepatic encephalopathy). Individuals with Alagille syndrome and progressive familial intrahepatic cholestasis may have hepatic impairment at baseline. Establish a baseline pattern of hepatic function variability prior to maralixibat initiation so that potential signs of liver injury can be identified. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, direct bilirubin, and INR at baseline and frequently for the first 6 to 8 months after starting maralixibat therapy and as clinically indicated thereafter during treatment. Monitor for elevations in liver tests, for the development of liver-related adverse reactions, and for physical signs of hepatic decompensation. Monitor individuals with compensated hepatic cirrhosis frequently. Decrease dose or interrupt treatment if new onset hepatic function abnormalities occur. Once hepatic function returns to baseline or stabilizes at a new baseline, consider restarting maralixibat at the last tolerated dose and increase as tolerated. Consider treatment discontinuation for persistent or recurrent hepatic function abnormalities or development of symptoms consistent with clinical hepatitis. Permanently discontinue treatment if an individual has persistent or recurrent liver test abnormalities, or upon rechallenge, signs and symptoms consistent with clinical hepatitis, or a hepatic decompensation event. Safety and efficacy of maralixibat have not been established in individuals with clinically significant portal hypertension or decompensated hepatic cirrhosis. Monitor individuals with compensated hepatic cirrhosis frequently and discontinue if hepatic decompensation occurs.[67014]
Maralixibat use during pregnancy is not expected to result in measurable fetal exposure due to low systemic absorption after oral administration. Maralixibat may inhibit the absorption of fat-soluble vitamins; increased fat-soluble vitamin supplementation may be needed during pregnancy. Monitor for fat-soluble vitamin deficiency and supplement as needed. In animal reproduction studies, no developmental effects were observed.[67014]
Use maralixibat with caution during breast-feeding. There are no data on the presence of maralixibat in human milk, its effects on the breast-fed child, or its effects on milk production. Maralixibat has low absorption after oral administration; breast-feeding is not expected to result in exposure to the child. Maralixibat may reduce the absorption of fat-soluble vitamins. Monitor fat-soluble vitamin concentrations and increase intake if deficiency is observed during lactation. Consider the benefits of breast-feeding, the patient's clinical need for treatment, and any potential adverse effects on the breast-fed child from the medication or from the underlying maternal medical condition.[67014]
Maralixibat contains propylene glycol (364.5 mg/mL). Infants and children younger than 5 years are at highest risk for propylene glycol toxicity, and a safe concentration for propylene glycol exposure with repeated administration in this population has not been established. The exposure to propylene glycol will be 14.6 mg/kg/day when maralixibat is administered at the dose (380 mcg/kg/dose once daily) for treatment of cholestatic pruritus in patients with ALGS. The exposure to propylene glycol will be 21.9 mg/kg/day when maralixibat is administered at the dose (570 mcg/kg/dose twice daily) for treatment of cholestatic pruritus in patients with PFIC. Use only the 19 mg/mL formulation of maralixibat in patients with PFIC in order to minimize exposure to propylene glycol. Consider the total daily intake of propylene glycol from all sources for managing the risk of propylene glycol toxicity. Monitor patients for signs of potential propylene glycol toxicity, including hemolysis, hyperosmolarity with anion gap metabolic acidosis, acute kidney injury, and CNS toxicity. Discontinue maralixibat if propylene glycol toxicity is suspected.[67014]
Maralixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). The mechanism by which maralixibat improves pruritus in individuals with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) is not completely understood; however, it may involve inhibition of the IBAT. Inhibition of the IBAT blocks the reabsorption of bile acids (primarily in the salt form) from the terminal ileum, interrupting enterohepatic circulation by shunting the bile acids away from the liver and towards fecal excretion which reduces the bile acid pool. Intrahepatic accumulation of bile acids can damage hepatic tissue and spill over into the systemic circulation.[66823][67014]
Pharmacodynamics
During a clinical trial, pediatric patients with ALGS were given maralixibat 380 mcg/kg daily for 13 weeks after an initial 5-week dose escalation period. In the majority of individuals, serum bile acid levels decreased from baseline as early as week 12 of treatment and the reduction was generally maintained for the treatment period. In pediatric patients with PFIC who received maralixibat 570 mcg/kg twice daily for up to 22 weeks after an initial 4 to 6 week dose escalation period, serum bile acid levels decreased from baseline in the majority of individuals as early as week 2. Serum bile acid levels fluctuated, but the reduction in serum bile acids was generally maintained for the treatment period.[67014]
Revision Date: 06/03/2025, 06:27:36 AMMaralixibat is administered orally. It is 91% protein bound; no maralixibat metabolites have been detected in plasma. Three minor metabolites have been detected in the feces, which account for less than 3% of maralixibat-associated fecal radioactivity. After a single dose of 30 mg maralixibat oral solution, maralixibat is primarily eliminated in the feces (73%, with 94% unchanged) with a mean half-life of 1.6 hours.[67014]
Affected cytochrome P450 isoenzymes and drug transporters: CYP3A4, OATP2B1
Maralixibat inhibits CYP3A4 in vitro; however, clinically significant drug interactions are not expected. Maralixibat inhibits the drug transporter OATP2B1 in vitro, which may result in reduced absorption of medications that rely on OATP2B1-mediated uptake in the GI tract. Maralixibat is not a substrate of the drug transporters MDR1 (P-gp), BCRP, OATP1B1, OATP1B3, or OATP2B2. In vitro, maralixibat does not induce CYP1A2, 2B6, or 3A4, nor inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, or 2D6 at clinically relevant concentrations. In vitro, maralixibat does not inhibit the transporters MDR1 (P-gp), BCRP, OAT1, OAT3, OATP1B1, OATP1B3, PEPT1, OCT1, OCT2, OCT3, OCTN1, OCTN2, MRP2, MATE1, or MATE2-K at clinically relevant concentrations.[67014]
Maralixibat is minimally absorbed after oral administration. Under fasted conditions, the AUC and Cmax of maralixibat oral solution increased in a dose-dependent manner with increases of 4.6- and 2.4-fold, respectively, after a 3.3-fold dose increase from 30 to 100 mg. After a single oral solution dose of 30 mg under fasted conditions, the median Tmax was 0.75 hour and the mean AUC and Cmax were 3.43 ng x hour/mL and 1.65 ng/mL, respectively. After administration of a single dose of 100 mg maralixibat tablet under fasted conditions, the AUC and Cmax were 13.2 ng x hour/mL and 3 ng/mL, respectively. The AUC and Cmax after a single 100 mg dose of maralixibat oral solution under the same conditions were 18.4 ng x hour/mL and 4.3 ng/mL, respectively. Due to the local site of action of maralixibat, the slightly lower exposure of the tablets compared to the oral solution is not clinically meaningful. Maralixibat accumulation was not observed after repeated oral administration in healthy adults at doses up to 100 mg once daily. The effect of food on the systemic exposure of maralixibat is not clinically significant. Concomitant administration with a high-fat meal decreased AUC and Cmax 64.8% and 85.8%, respectively.[67014]
The pharmacokinetics of maralixibat were not studied in individuals with impaired renal function, including those with end-stage renal disease or those on hemodialysis.[67014]
Due to low systemic absorption, maralixibat levels in pediatric patients were below the limit of quantification (0.25 ng/mL) in the majority of plasma samples during clinical trials.[67014]
Maralixibat use during pregnancy is not expected to result in measurable fetal exposure due to low systemic absorption after oral administration. Maralixibat may inhibit the absorption of fat-soluble vitamins; increased fat-soluble vitamin supplementation may be needed during pregnancy. Monitor for fat-soluble vitamin deficiency and supplement as needed. In animal reproduction studies, no developmental effects were observed.[67014]
Use maralixibat with caution during breast-feeding. There are no data on the presence of maralixibat in human milk, its effects on the breast-fed child, or its effects on milk production. Maralixibat has low absorption after oral administration; breast-feeding is not expected to result in exposure to the child. Maralixibat may reduce the absorption of fat-soluble vitamins. Monitor fat-soluble vitamin concentrations and increase intake if deficiency is observed during lactation. Consider the benefits of breast-feeding, the patient's clinical need for treatment, and any potential adverse effects on the breast-fed child from the medication or from the underlying maternal medical condition.[67014]
Cookies are used by this site. To decline or learn more, visit our cookie notice.
Copyright © 2025 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.